The United States Food and Drug Administration (USFDA) has conducted an inspection of the API manufacturing facility, at Baddi, Himachal Pradesh, of Morepen Laboratories. The facility has been cleared by USFDA on March 24, 2023 without any adverse observation (NIL 483).
Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.